None
Quote | Xeris Pharmaceuticals Inc. (NASDAQ:XERS)
Last: | $2.08 |
---|---|
Change Percent: | 0.97% |
Open: | $2.07 |
Close: | $2.06 |
High: | $2.08 |
Low: | $2.04 |
Volume: | 123,439 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Xeris Pharmaceuticals Inc. (NASDAQ:XERS)
2024-06-11 12:08:45 ET Summary Corcept Therapeutics Incorporated share prices were initially suppressed after a court ruling that Teva's generic version of Korlym would not infringe on its patents. However, the company is preparing an NDA for Korlym's successor, which could be app...
In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower maintenance dose requirements and lower rates of potentially clinically important liver-re...
Message Board Posts | Xeris Pharmaceuticals Inc. (NASDAQ:XERS)
Subject | By | Source | When |
---|---|---|---|
Izzy Englander likes $XERS... | price_and_volume | investorshub | 05/27/2022 8:39:29 PM |
Anybody know what this is G85CVR010 ? It-showed-in-my-TD-acct-after | mess124 | investorshub | 01/20/2022 1:17:06 AM |
Yes indeed | Elgordo84 | investorshub | 12/31/2021 4:50:55 PM |
Nice catch in the low 2.00s. | alchemytrader | investorshub | 12/31/2021 1:22:50 PM |
Goodluck to all the Longs! | Elgordo84 | investorshub | 11/15/2021 2:41:48 PM |
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower maintenance dose requirements and lower rates of potentially clinically important liver-re...
XeriSol™ formulation enabled predictable bioavailability and sustained levels of levothyroxine in a once-weekly subcutaneous presentation Once-weekly SC levothyroxine (XP-8121) participants normalized TSH/T4 levels using 45% less drug than would be needed for their daily oral dose ...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a f...